Simultaneous Human Immunodeficiency Virus-Hepatitis B-Hepatitis C Point-of-Care Tests Improve Outcomes in Linkage-to-Care: Results of a Randomized Control Trial in Persons Without Healthcare Coverage

Bottéro, J.; Boyd, Anders; Gozlan, Joël; Carrat, Fabrice; Nau, Jean; Pauti, M.-D.; Rougier, Hayette; Girard, Pierre‐Marie; Lacombe, Karine

doi:10.1093/ofid/ofv162

Cited by 68 publications

(61 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a systematic review of the effectiveness of interventions to improve hepatitis C testing among PWID, on‐site testing with pre‐test discussion and education and dried blood spot (DBS) testing were demonstrated to be effective in increasing hepatitis C testing among PWID when compared to control interventions . Other strategies that have been evaluated (without any comparator intervention) include physical and electronic medical chart reminders to prompt targeted risk‐based assessment and testing, peer‐delivered outreach hepatitis C testing and hepatitis C education, prison‐based outreach testing, patient referral contact tracing with monetary incentive for testing and point‐of‐care hepatitis C testing . Decisions on what intervention(s) to implement to enhance hepatitis C testing will depend on the setting (and prevalence of hepatitis C infection), the model of care, the local context and health care system.…”

Section: Interventions To Enhance Hepatitis C Prevention Testing Andmentioning

confidence: 99%

“…Integrated hepatitis C care within drug use and psychiatric services delivered by a multidisciplinary team with case management services, with or without non‐invasive liver disease assessment, was associated with improved hepatitis C treatment uptake . Other strategies evaluated and shown to enhance hepatitis C linkage to care and treatment include dried blood spot testing, point‐of‐care hepatitis C testing, non‐invasive liver disease screening using transient elastography (FibroScan ® ) with facilitated referral to care, integrated hepatitis C care, patient navigation programmes, peer‐based support, financial incentive programmes and telemedicine . However, the majority of interventions that have been evaluated are specific for the interferon‐era.…”

Section: Interventions To Enhance Hepatitis C Prevention Testing Andmentioning

confidence: 99%

See 1 more Smart Citation

Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework

Day

Hellard

Treloar

et al. 2018

Liver International

105

View full text Add to dashboard Cite

The burden of hepatitis C infection is considerable among people who inject drugs (PWID), with an estimated prevalence of greater than 40%, representing an estimated 5.6 million people who have recently injected drugs living with hepatitis C infection. As such, PWID are a priority population for enhancing prevention, testing, linkage to care, treatment and follow-up care in order to meet World Health Organization (WHO) hepatitis C elimination goals by 2030. There are many barriers to enhancing hepatitis C prevention and care among PWID including; poor global coverage of harm reduction services, restrictive drug policies and criminalization of drug use, poor access to health services, low hepatitis C testing, linkage to care and treatment, restrictions for accessing DAA therapy, and the lack of national strategies and government investment to support WHO elimination goals. On 5 September 2017, the International Network of Hepatitis in Substance Users (INHSU) held a roundtable panel of international experts to discuss remaining challenges and future priorities for action from a health systems perspective. The WHO health systems framework comprises six core components; service delivery, health workforce, health information systems, medical procurement, health systems financing, and leadership and governance. Communication has been proposed as a seventh key element which promotes the central role of affected community engagement. This review paper presents recommended strategies for eliminating hepatitis C as a major public health threat among PWID and outlines future priorities for action within a health systems framework. This article is protected by copyright. All rights reserved.

show abstract

Section: Interventions To Enhance Hepatitis C Prevention Testing Andmentioning

confidence: 99%

Section: Interventions To Enhance Hepatitis C Prevention Testing Andmentioning

confidence: 99%

Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework

Day

Hellard

Treloar

et al. 2018

Liver International

105

View full text Add to dashboard Cite

show abstract

“…Potential strategies to improve HCV testing include education and counseling by health professionals with on-site HCV testing (Cullen et al, 2006; Lacey, Ellen, Devlin, Wright, & Mijch, 2007; Meyer et al, 2015; Rosenberg et al, 2010; Sahajian et al, 2011; Zhou et al, 2016), physical and electronic medical chart reminders to prompt targeted risk-based assessment and testing (Drainoni et al, 2012; Krauskopf et al, 2014; Litwin et al, 2012; Meyer et al, 2015; Zhou et al, 2016), and simplified testing, including dried blood spot testing (Abou-Saleh, Rice, & Foley, 2013; Coats & Dillon, 2015; Craine, O'Toole, D'Arcy, & Lyons, 2009; Hickman et al, 2008; McLeod et al, 2014; Meyer et al, 2015; Tait, Stephens, McIntyre, Evans, & Dillon, 2013; Zhou et al, 2016), and point-of-care HCV testing (Beckwith et al, 2016; Bottero et al, 2015; Morano et al, 2014). …”

Section: Hcv Testingmentioning

confidence: 99%

“…Simplified HCV testing, including dried blood spot testing (McAllister et al, 2014) and point-of-care HCV testing (Bottero et al, 2015; Morano et al, 2014) has been shown to facilitate linkage to HCV care. Other strategies that have been demonstrated to facilitate linkage to HCV care and treatment include, non-invasive liver disease screening using transient elastography (FibroScan ® ) with facilitated referral to care (Foucher et al, 2009; Marshall et al, 2015; Moessner et al, 2011), integrated HCV care (Cullen et al, 2006; Evon et al, 2011; Ho et al, 2015; Knott et al, 2006; Masson et al, 2013; Zhou et al, 2016), patient navigation programs (Falade-Nwulia et al, 2016; Trooskin et al, 2015), and telemedicine (Arora et al, 2011; Lloyd et al, 2013; Mashru, Kirlew, Saginur, & Schreiber, 2017; Tahan, Almashhrawi, Kahveci, Mutrux, & Ibdah, 2016).…”

Section: Linkage To Hcv Care and Treatmentmentioning

confidence: 99%

Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs

Grebely

Bruneau

Lazarus

et al. 2017

International Journal of Drug Policy

View full text Add to dashboard Cite

Globally, it is estimated that 71.1 million people have chronic hepatitis C virus (HCV) infection, including an estimated 7. 5 million people who have recently injected drugs (PWID). There is an additional large, but unquantified, burden among those PWID who have ceased injecting. The incidence of HCV infection among current PWID also remains high in many settings. Morbidity and mortality due to liver disease among PWID with HCV infection continues to increase, despite the advent of well-tolerated, simple interferon-free direct-acting antiviral (DAA) HCV regimens with cure rates >95%. As a result of this important clinical breakthrough, there is potential to reverse the rising burden of advanced liver disease with increased treatment and strive for HCV elimination among PWID. Unfortunately, there are many gaps in knowledge that represent barriers to effective prevention and management of HCV among PWID. The Kirby Institute, UNSW Sydney and the International Network on Hepatitis in Substance Users (INHSU) established an expert round table panel to assess current research gaps and establish future research priorities for the prevention and management of HCV among PWID. This round table consisted of a one-day workshop held on 6 September, 2016, in Oslo, Norway, prior to the International Symposium on Hepatitis in Substance Users (INHSU 2016). International experts in drug and alcohol, infectious diseases, and hepatology were brought together to discuss the available scientific evidence, gaps in research, and develop research priorities. Topics for discussion included the epidemiology of injecting drug use, HCV, and HIV among PWID, HCV prevention, HCV testing, linkage to HCV care and treatment, DAA treatment for HCV infection, and reinfection following successful treatment. This paper highlights the outcomes of the roundtable discussion focused on future research priorities for enhancing HCV prevention, testing, linkage to care and DAA treatment for PWID as we strive for global elimination of HCV infection.

show abstract

“…Applying lessons learned from annual syphilis screening efforts in HIV when considering annual HCV testing in HIV-infected MSM, could improve opportunities to identify and cure incident cases in HIV-infected persons [80]. Because most persons with HCV and HBV infection and 15–30% of those with HIV-infection in the US and Europe remain undiagnosed, increased uptake of simultaneous point-of-care testing for HIV, HCV, and HBV in high-risk populations merits consideration [81]. While emergency rooms represent an opportunity to increase HCV and HIV diagnoses through opt-out testing [82], barriers to linkage to care persist and require dedicated resources [83].…”

Section: Diagnosis Cost and Accessmentioning

confidence: 99%

Update in HIV–hepatitis C virus coinfection in the direct acting antiviral era

Meissner

2017

Current Opinion in Gastroenterology

View full text Add to dashboard Cite

Purpose of Review Availability of direct acting antivirals (DAAs) that demonstrate remarkable clinical efficacy and safety has revolutionized the ability to treat chronic infection with hepatitis C virus (HCV). An equal measure of clinical success has now been achieved in persons co-infected with HCV and the human immunodeficiency virus (HIV), a historically harder to cure cohort with interferon-based therapy. Global goals include identifying all HIV/HCV-infected persons, gaining access to DAA-therapy, preventing de novo and re-infection, and managing the sequelae of chronic infection. This review will discuss advances in the field of HIV/HCV co-infection reported during the last 18 months, and will suggest areas for future investigation. Recent Findings An expanding body of literature has enhanced our understanding of the clinical and epidemiologic issues surrounding HIV/HCV co-infection. DAA therapy for HCV is highly efficacious in HIV/HCV co-infected persons if drug-drug interactions are appropriately considered. Summary Eradicating HCV infection in persons with HIV co-infection can be achieved safely and effectively with available DAAs. Economic and social approaches to enable access and delivery of curative HCV therapy to HIV-infected persons require continued research and resource allocation.

show abstract

Simultaneous Human Immunodeficiency Virus-Hepatitis B-Hepatitis C Point-of-Care Tests Improve Outcomes in Linkage-to-Care: Results of a Randomized Control Trial in Persons Without Healthcare Coverage

Cited by 68 publications

References 32 publications

Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework

Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework

Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs

Update in HIV–hepatitis C virus coinfection in the direct acting antiviral era

Contact Info

Product

Resources

About